PAMP
THRD

Polar Asset Management Partners’s Third Harmonic Bio THRD Stock Holding History

Polar Asset Management Partners’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,596
Closed -$220K – 1313
2022
Q3 		$220K Buy
+11,596
New +$209K ﹤0.01% 849

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Asset Management Partners's THRD Position: Q4 2022 in Review

Polar Asset Management Partners sold out of Third Harmonic Bio (THRD) in Q4 2022, closing a stake of 11,596 shares — an estimated $220K sold.

Polar Asset Management Partners first reported a position in THRD in Q3 2022 and held it in 1 quarter. The position peaked at $220K in Q3 2022. 50 funds tracked by Wall St. Rank hold THRD as of Q4 2022.

  • Polar Asset Management Partners reported no remaining Third Harmonic Bio position as of Q4 2022 after selling out during the quarter.
  • Polar Asset Management Partners sold 11,596 Third Harmonic Bio shares in Q4 2022, an estimated $220K.
  • Polar Asset Management Partners first reported a position in Third Harmonic Bio in Q3 2022 and held it in 1 quarter.
  • Polar Asset Management Partners's Third Harmonic Bio position peaked at $220K in Q3 2022.
  • 50 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2022.

Based on Polar Asset Management Partners's 13F filing for Q4 2022, filed 14 Feb 2023.